Under the agreement, Strides will develop and supply injectable products that Sagent will market in the US.
Jeffrey Yordon, CEO, founder and chairman of the board of Sagent, said: “This joint venture is an important step in Sagent’s establishing a deep, consistent pipeline of quality products. The strength and experience of our sales organization as well as our marketing and distribution capabilities coupled with Strides’ extensive development and manufacturing expertise positions us strongly in the specialty injectable market. We are extremely pleased to be working with an organization of Strides’ caliber.”
Arun Kumar, Strides’ founder and managing director, said: “We are extremely pleased with our new joint venture with Sagent for a range of specialty injectables and are confident that the partnership will create value for our stakeholders and enrich Sagent’s offering of quality pharmaceutical products.”